Biomaterial Database

von Willebrand factor abnormalities in two patients with uraemia. 1988

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

UI	MeSH Term	Description	Entries
D008297	Male		Males
D010314	Partial Thromboplastin Time	The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.	Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D005169	Factor VIII	Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.	Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005260	Female		Females
D006487	Hemostasis	The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.	Hemostases
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D014511	Uremia	A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	Uremias
D014841	von Willebrand Factor	A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.	Factor VIII-Related Antigen,Factor VIIIR-Ag,Factor VIIIR-RCo,Plasma Factor VIII Complex,Ristocetin Cofactor,Ristocetin-Willebrand Factor,von Willebrand Protein,Factor VIII Related Antigen,Factor VIIIR Ag,Factor VIIIR RCo,Ristocetin Willebrand Factor

Related Publications

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

[Acquired von Willebrand factor abnormalities].

March 1992, Rinsho byori. The Japanese journal of clinical pathology,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia.

March 1988, The Keio journal of medicine,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

Von Willebrand factor abnormalities in IgA nephropathy.

March 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibship.

February 1986, American journal of hematology,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease.

July 1988, Blood,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.

August 1994, Blood,

F Rodeghiero, and G Castaman, and R Lombardi, and P M Mannucci

von Willebrand factor abnormalities in primary pulmonary hypertension.

February 1987, The American review of respiratory disease,